Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy

Virology

Volumn 423, Issue 2, 2012, Pages 107-118

  Horiike, Mariko ^a   Iwami, Shingo ^a,b,c   Kodama, Makoto ^d   Sato, Akihiko ^d   Watanabe, Yuji ^a   Yasui, Mika ^a   Ishida, Yuki ^a   Kobayashi, Takeshi ^a   Miura, Tomoyuki ^a   Igarashi, Tatsuhiko ^a  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d SHIONOGI AND CO LTD   (Japan)

Author keywords

Animal model; Antiretroviral therapy; HAART; HIV 1; Rebound of plasma viremia; Reservoirs; SIV

Indexed keywords

ATAZANAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEF PROTEIN; SAQUINAVIR; TENOFOVIR DISOPROXIL; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE CARRIER; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTESTINE; LENTIVIRUS INFECTION; LUNG PARENCHYMA; LYMPH NODE; LYMPHOID TISSUE; MATHEMATICAL MODEL; MESENTERY LYMPH NODE; MORNING DOSAGE; NONHUMAN; PRIORITY JOURNAL; REBOUND; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS INFECTION; T LYMPHOCYTE; TISSUE DISTRIBUTION; TREATMENT DURATION; VIRUS DETECTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESERVOIR;

ANIMALS; ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DISEASE RESERVOIRS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LYMPH NODES; MACACA MULATTA; RECURRENCE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS LATENCY; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84855767273     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.11.024     Document Type: Article

References (63)

1. Balzarini J., Weeger M., Camarasa M.J., De Clercq E., Uberla K. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem. Biophys. Res. Commun. 1995, 211(3):850-856.
2. Benlhassan-Chahour K., Penit C., Dioszeghy V., Vasseur F., Janvier G., Riviere Y., Dereuddre-Bosquet N., Dormont D., Le Grand R., Vaslin B. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J. Virol. 2003, 77(23):12479-12493.
3. Bourry O., Mannioui A., Sellier P., Roucairol C., Durand-Gasselin L., Dereuddre-Bosquet N., Benech H., Roques P., Le Grand R. Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology 2010, 7:78.
4. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., Nguyen P.L., Khoruts A., Larson M., Haase A.T., Douek D.C. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 2004, 200(6):749-759.
5. Brennan T.P., Woods J.O., Sedaghat A.R., Siliciano J.D., Siliciano R.F., Wilke C.O. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J. Virol. 2009, 83(17):8470-8481.
6. Burton G.F., Keele B.F., Estes J.D., Thacker T.C., Gartner S. Follicular dendritic cell contributions to HIV pathogenesis. Semin. Immunol. 2002, 14(4):275-284.
7. Buzon M.J., Massanella M., Llibre J.M., Esteve A., Dahl V., Puertas M.C., Gatell J.M., Domingo P., Paredes R., Sharkey M., Palmer S., Stevenson M., Clotet B., Blanco J., Martinez-Picado J. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat. Med. 2010, 16(4):460-465.
8. Chun T.W., Davey R.T., Engel D., Lane H.C., Fauci A.S. Re-emergence of HIV after stopping therapy. Nature 1999, 401(6756):874-875.
9. Chun T.W., Davey R.T., Ostrowski M., Shawn Justement J., Engel D., Mullins J.I., Fauci A.S. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat. Med. 2000, 6(7):757-761.
10. Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A., Baseler M., Lloyd A.L., Nowak M.A., Fauci A.S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(24):13193-13197.
11. Cline A.N., Bess J.W., Piatak M., Lifson J.D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 2005, 34(5-6):303-312.
12. Connick E., Mattila T., Folkvord J.M., Schlichtemeier R., Meditz A.L., Ray M.G., McCarter M.D., Mawhinney S., Hage A., White C., Skinner P.J. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J. Immunol. 2007, 178(11):6975-6983.
13. Dinoso J.B., Rabi S.A., Blankson J.N., Gama L., Mankowski J.L., Siliciano R.F., Zink M.C., Clements J.E. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J. Virol. 2009, 83(18):9247-9257.
14. Douek D.C., Picker L.J., Koup R.A. T cell dynamics in HIV-1 infection. Annu. Rev. Immunol. 2003, 21:265-304.
15. Du Bois D., Du Bois E.F. The measurement of the surface area of man. Arch. Intern. Med. 1915, 15:868-881.
16. Du Bois D., Du Bois E.F. A formula to estimate the approximate surface area if height and weight be known. Arch. Intern. Med. 1916, 17:863-871.
17. Efron B. 1977 Rietz lecture - bootstrap methods - another look at the Jackknife. Ann. Stat. 1979, 7(1):1-26.
18. Efron B., Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat. Sci. 1986, 1:54-75.
19. Embretson J., Zupancic M., Ribas J.L., Burke A., Racz P., Tenner-Racz K., Haase A.T. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993, 362(6418):359-362.
20. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278(5341):1295-1300.
21. Folkvord J.M., Armon C., Connick E. Lymphoid follicles are sites of heightened human immunodeficiency virus type 1 (HIV-1) replication and reduced antiretroviral effector mechanisms. AIDS Res. Hum. Retroviruses 2005, 21(5):363-370.
22. Fortman J.D., Hewett T.A., Bennett B.T. The Laboratory Nonhuman Primate 2001, CRC Press, New York.
23. Frappier S., Breilh D., Diarte E., Ba B., Ducint D., Pellegrin J.L., Saux M.C. Simultaneous determination of ritonavir and saquinavir, two human immunodeficiency virus protease inhibitors, in human serum by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 1998, 714(2):384-389.
24. Frost S.D., Gunthard H.F., Wong J.K., Havlir D., Richman D.D., Leigh Brown A.J. Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. Virology 2001, 284(2):250-258.
25. Giuffre A.C., Higgins J., Buckheit R.W., North T.W. Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob. Agents Chemother. 2003, 47(5):1756-1759.
26. Guadalupe M., Reay E., Sankaran S., Prindiville T., Flamm J., McNeil A., Dandekar S. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J. Virol. 2003, 77(21):11708-11717.
27. Harada S., Koyanagi Y., Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985, 229(4713):563-566.
28. Havlir D.V., Strain M.C., Clerici M., Ignacio C., Trabattoni D., Ferrante P., Wong J.K. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J. Virol. 2003, 77(20):11212-11219.
29. Igarashi T., Brown C., Azadegan A., Haigwood N., Dimitrov D., Martin M.A., Shibata R. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat. Med. 1999, 5(2):211-216.
30. Igarashi T., Brown C.R., Byrum R.A., Nishimura Y., Endo Y., Plishka R.J., Buckler C., Buckler-White A., Miller G., Hirsch V.M., Martin M.A. Rapid and irreversible CD4+ T-cell depletion induced by the highly pathogenic simian/human immunodeficiency virus SHIV(DH12R) is systemic and synchronous. J. Virol. 2002, 76(1):379-391.
31. Inaba K., Fukazawa Y., Matsuda K., Himeno A., Matsuyama M., Ibuki K., Miura Y., Koyanagi Y., Nakajima A., Blumberg R.S., Takahashi H., Hayami M., Igarashi T., Miura T. Small intestine CD4+ cell reduction and enteropathy in simian/human immunodeficiency virus KS661-infected rhesus macaques in the presence of low viral load. J. Gen. Virol. 2009, 91(Pt 3):773-781.
32. Keele B.F., Tazi L., Gartner S., Liu Y., Burgon T.B., Estes J.D., Thacker T.C., Crandall K.A., McArthur J.C., Burton G.F. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J. Virol. 2008, 82(11):5548-5561.
33. Kestler H., Kodama T., Ringler D., Marthas M., Pedersen N., Lackner A., Regier D., Sehgal P., Daniel M., King N., et al. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science 1990, 248(4959):1109-1112.
34. Koyanagi Y., Harada S., Yamamoto N. Establishment of a high production system for AIDS retroviruses with a human T-leukemic cell line Molt-4. Cancer Lett. 1986, 30(3):299-310.
35. Markowitz M., Louie M., Hurley A., Sun E., Di Mascio M., Perelson A.S., Ho D.D. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 2003, 77(8):5037-5038.
36. Martinez M.A., Cabana M., Ibanez A., Clotet B., Arno A., Ruiz L. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology 1999, 256(2):180-187.
37. Meng G., Sellers M.T., Mosteller-Barnum M., Rogers T.S., Shaw G.M., Smith P.D. Lamina propria lymphocytes, not macrophages, express CCR5 and CXCR4 and are the likely target cell for human immunodeficiency virus type 1 in the intestinal mucosa. J. Infect. Dis. 2000, 182(3):785-791.
38. Miyake A., Ibuki K., Enose Y., Suzuki H., Horiuchi R., Motohara M., Saito N., Nakasone T., Honda M., Watanabe T., Miura T., Hayami M. Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection. J. Gen. Virol. 2006, 87(Pt 5):1311-1320.
39. Murray J.M., Emery S., Kelleher A.D., Law M., Chen J., Hazuda D.J., Nguyen B.Y., Teppler H., Cooper D.A. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007, 21(17):2315-2321.
40. North T.W., Higgins J., Deere J.D., Hayes T.L., Villalobos A., Adamson L., Shacklett B.L., Schinazi R.F., Luciw P.A. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J. Virol. 2009, 84(6):2913-2922.
41. Palmer S., Maldarelli F., Wiegand A., Bernstein B., Hanna G.J., Brun S.C., Kempf D.J., Mellors J.W., Coffin J.M., King M.S. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(10):3879-3884.
42. Pantaleo G., Graziosi C., Demarest J.F., Butini L., Montroni M., Fox C.H., Orenstein J.M., Kotler D.P., Fauci A.S. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993, 362(6418):355-358.
43. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20(4):309-321.
44. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M., Ho D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387(6629):188-191.
45. Perelson A.S., Nelson P.W. Mathematical analysis of HIV-1 dynamics in vivo. Siam Rev. 1999, 41(1):3-44.
46. Popovic M., Sarngadharan M.G., Read E., Gallo R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224(4648):497-500.
47. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22(3):659-661.
48. Reed L., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
49. Richman D.D. HIV chemotherapy. Nature 2001, 410(6831):995-1001.
50. Sato A., Kodama M., Abe K., Miki S., Nishimura M., Suyama A., Ogata M., Toyoda T., Sugimoto H., Yoshie O., et al. A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice. Antiviral Res. 1995, 27(1-2):151-163.
51. Sharkey M., Babic D.Z., Greenough T., Gulick R., Kuritzkes D.R., Stevenson M. Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure. PLoS Pathog. 2011, 7(2):e1001303.
52. Sharkey M., Triques K., Kuritzkes D.R., Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J. Virol. 2005, 79(8):5203-5210.
53. Sharkey M.E., Teo I., Greenough T., Sharova N., Luzuriaga K., Sullivan J.L., Bucy R.P., Kostrikis L.G., Haase A., Veryard C., Davaro R.E., Cheeseman S.H., Daly J.S., Bova C., Ellison R.T., Mady B., Lai K.K., Moyle G., Nelson M., Gazzard B., Shaunak S., Stevenson M. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. 2000, 6(1):76-81.
54. Shibata R., Kawamura M., Sakai H., Hayami M., Ishimoto A., Adachi A. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J. Virol. 1991, 65(7):3514-3520.
55. Siliciano J.D., Kajdas J., Finzi D., Quinn T.C., Chadwick K., Margolick J.B., Kovacs C., Gange S.J., Siliciano R.F. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 2003, 9(6):727-728.
56. Spiegel H., Herbst H., Niedobitek G., Foss H.D., Stein H. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am. J. Pathol. 1992, 140(1):15-22.
57. Thacker T.C., Zhou X., Estes J.D., Jiang Y., Keele B.F., Elton T.S., Burton G.F. Follicular dendritic cells and human immunodeficiency virus type 1 transcription in CD4+ T cells. J. Virol. 2009, 83(1):150-158.
58. Van Rompay K.K., Brignolo L.L., Meyer D.J., Jerome C., Tarara R., Spinner A., Hamilton M., Hirst L.L., Bennett D.R., Canfield D.R., Dearman T.G., Von Morgenland W., Allen P.C., Valverde C., Castillo A.B., Martin R.B., Samii V.F., Bendele R., Desjardins J., Marthas M.L., Pedersen N.C., Bischofberger N. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob. Agents Chemother. 2004, 48(5):1469-1487.
59. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., Rosenzweig M., Johnson R.P., Desrosiers R.C., Lackner A.A. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280(5362):427-431.
60. Veazey R.S., Mansfield K.G., Tham I.C., Carville A.C., Shvetz D.E., Forand A.E., Lackner A.A. Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection. J. Virol. 2000, 74(23):11001-11007.
61. Witvrouw M., Pannecouque C., Switzer W.M., Folks T.M., De Clercq E., Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 2004, 9(1):57-65.
62. Wong J.K., Hezareh M., Gunthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278(5341):1291-1295.
63. Department of Health and Human Services (DHHS) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.